+

WO2000066731A3 - Recombinant laminin 5 - Google Patents

Recombinant laminin 5 Download PDF

Info

Publication number
WO2000066731A3
WO2000066731A3 PCT/US2000/011459 US0011459W WO0066731A3 WO 2000066731 A3 WO2000066731 A3 WO 2000066731A3 US 0011459 W US0011459 W US 0011459W WO 0066731 A3 WO0066731 A3 WO 0066731A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant laminin
methods
laminin
recombinant
migration
Prior art date
Application number
PCT/US2000/011459
Other languages
French (fr)
Other versions
WO2000066731A2 (en
Inventor
Ariel Boutaud
Original Assignee
Biostatum Inc
Ariel Boutaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biostatum Inc, Ariel Boutaud filed Critical Biostatum Inc
Priority to JP2000615755A priority Critical patent/JP2002542824A/en
Priority to AU46753/00A priority patent/AU4675300A/en
Priority to EP00928524A priority patent/EP1177290A2/en
Publication of WO2000066731A2 publication Critical patent/WO2000066731A2/en
Publication of WO2000066731A3 publication Critical patent/WO2000066731A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/22—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using chemical indicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)

Abstract

The present invention provides recombinant laminin 5, methods for making recombinant laminin 5, cells that express recombinant laminin 5, and methods for using the recombinant laminin 5 to accelerate wound healing, and to promote cell attachment and migration.
PCT/US2000/011459 1999-04-30 2000-04-28 Recombinant laminin 5 WO2000066731A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2000615755A JP2002542824A (en) 1999-04-30 2000-04-28 Recombinant laminin 5
AU46753/00A AU4675300A (en) 1999-04-30 2000-04-28 Recombinant laminin 5
EP00928524A EP1177290A2 (en) 1999-04-30 2000-04-28 Recombinant laminin 5

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13172099P 1999-04-30 1999-04-30
US14973899P 1999-08-21 1999-08-21
US60/149,738 1999-08-21
US15594599P 1999-09-24 1999-09-24
US60/155,945 1999-09-24
US60/131,720 1999-09-24

Publications (2)

Publication Number Publication Date
WO2000066731A2 WO2000066731A2 (en) 2000-11-09
WO2000066731A3 true WO2000066731A3 (en) 2001-06-28

Family

ID=27384196

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/011459 WO2000066731A2 (en) 1999-04-30 2000-04-28 Recombinant laminin 5

Country Status (4)

Country Link
EP (1) EP1177290A2 (en)
JP (1) JP2002542824A (en)
AU (1) AU4675300A (en)
WO (1) WO2000066731A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933273B2 (en) 2000-12-21 2005-08-23 Karl Tryggvason Isolated laminin 10
WO2004108927A1 (en) * 2003-06-04 2004-12-16 Yokohama Tlo Company, Ltd. Laminin 5b
JP4566603B2 (en) * 2004-03-31 2010-10-20 財団法人かずさディー・エヌ・エー研究所 Cell attachment polypeptide
FR2873698B1 (en) * 2004-07-29 2006-10-20 D Anjou Sa Lab NEW PEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
CA2598696A1 (en) * 2005-02-23 2006-08-31 Surmodics, Inc. Implantable medical articles having laminin coatings and methods of use
FR2943062B1 (en) 2009-03-13 2011-04-08 Symatese NEW PEPTIDE PROMOTING CELL ADHESION AND MIGRATION
WO2015080297A1 (en) 2013-11-27 2015-06-04 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
CA2965770C (en) * 2014-10-31 2024-02-13 Kyoto Prefectural Public University Corporation Treatment of cornea using laminin
US11918630B2 (en) 2014-10-31 2024-03-05 Kyoto Prefectural Public University Corporation Treatment of retina and nerve using laminin
JP6792852B2 (en) * 2016-06-07 2020-12-02 国立大学法人 岡山大学 Keratinized gingival inducer
AU2018262323A1 (en) * 2017-05-05 2019-11-21 National University Of Singapore Methods for culturing human keratinocytes
FR3127219B1 (en) 2021-09-20 2025-04-11 Laboratoires Danjou NEW PEPTIDES AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINERS THEREOF

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204302A2 (en) * 1985-06-03 1986-12-10 Meloy Laboratories, Inc. Laminin and the production thereof
WO1994005316A1 (en) * 1992-08-28 1994-03-17 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Products and methods for improving keratinocyte adhesion to the dermis
WO1995011972A1 (en) * 1993-10-27 1995-05-04 The General Hospital Corporation B1k CHAIN OF LAMININ AND METHODS OF USE
WO1995013103A2 (en) * 1993-11-12 1995-05-18 Desmos, Inc. Soluble factor stimulation of attachment and hemidesmosome assembly in epithelial cells
WO1996010646A1 (en) * 1994-10-04 1996-04-11 Karl Tryggvason Laminin chains: diagnostic and therapeutic use
WO1997012961A2 (en) * 1995-10-06 1997-04-10 Desmos, Inc. Growth of adult pancreatic islet cells with laminin 5
WO1997036621A1 (en) * 1996-03-29 1997-10-09 Desmos, Inc. Cellular attachment to laminin 5-coated trans-epithelial appliances
WO1997047652A1 (en) * 1996-06-10 1997-12-18 Desmos, Inc. Purification of soluble laminin 5
WO1997048415A1 (en) * 1996-06-05 1997-12-24 The General Hospital Corporation Laminin-5 and the formation of basement membrane structure
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0204302A2 (en) * 1985-06-03 1986-12-10 Meloy Laboratories, Inc. Laminin and the production thereof
WO1994005316A1 (en) * 1992-08-28 1994-03-17 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Products and methods for improving keratinocyte adhesion to the dermis
WO1995011972A1 (en) * 1993-10-27 1995-05-04 The General Hospital Corporation B1k CHAIN OF LAMININ AND METHODS OF USE
WO1995013103A2 (en) * 1993-11-12 1995-05-18 Desmos, Inc. Soluble factor stimulation of attachment and hemidesmosome assembly in epithelial cells
WO1996010646A1 (en) * 1994-10-04 1996-04-11 Karl Tryggvason Laminin chains: diagnostic and therapeutic use
WO1997012961A2 (en) * 1995-10-06 1997-04-10 Desmos, Inc. Growth of adult pancreatic islet cells with laminin 5
WO1997036621A1 (en) * 1996-03-29 1997-10-09 Desmos, Inc. Cellular attachment to laminin 5-coated trans-epithelial appliances
WO1997048415A1 (en) * 1996-06-05 1997-12-24 The General Hospital Corporation Laminin-5 and the formation of basement membrane structure
WO1997047652A1 (en) * 1996-06-10 1997-12-18 Desmos, Inc. Purification of soluble laminin 5
WO1998011217A2 (en) * 1996-09-13 1998-03-19 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAGNOUX-PALACIOS L ET AL: "Functional re-expression of laminin-5 in laminin-gamma2-deficient human keratinocytes modifies cell morphology, motility, and adhesion", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 271, no. 21, 2 August 1996 (1996-08-02), pages 18437 - 18444, XP002154950 *
MATSUI C ET AL: "The assembly of laminin-5 subunits", JOURNAL OF BIOLOGICAL CHEMISTRY., vol. 270, no. 40, 6 October 1995 (1995-10-06), pages 23496 - 23503, XP002154951 *
NICOSIA R ET AL: "Modulation of angiogenesis in vitro by laminin-entactin complex", DEV BIOL, vol. 164, no. 1, July 1994 (1994-07-01), pages 197 - 206, XP000971040 *
VAILLY J ET AL: "Corrective gene transfer of keratinocytes from patients with junctional epidermolysis bullosa restores assembly of hemidesmosomes in reconstructed epithelia", GENE THER., vol. 5, no. 10, October 1998 (1998-10-01), pages 1322 - 1332, XP000961159 *

Also Published As

Publication number Publication date
AU4675300A (en) 2000-11-17
EP1177290A2 (en) 2002-02-06
JP2002542824A (en) 2002-12-17
WO2000066731A2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
WO2000066730A3 (en) Laminin 2 and methods for its use
IL144654A0 (en) Pancreatic progenitor cells, methods and uses related thereto
IL147803A0 (en) 28-epirapalogs
AU5850200A (en) Positive plate active material, method for producing the same, and secondary cell
EP1024502A4 (en) Composition for electrolyte, electrolyte and process for producing the same, and cell containing the same
MXPA01011968A (en) Materials and processes for providing fuel cells and active membranes.
IL143529A0 (en) An electrolysis cell and methods utilizing the same
ZA978256B (en) Electrolyte.
AU2748201A (en) Graft polymerization, separators, and batteries including the separators
MXPA01005732A (en) Pentacyclic triterpenes.
MXPA03007829A (en) Novel fuel cell cathodes and their fuel cells.
HK1045763A1 (en) Fuel assembly and method for use with the fuel cell assembly.
ZA971182B (en) Electrochemical cell.
WO2000066731A3 (en) Recombinant laminin 5
GR3032605T3 (en) Sugar-modified cytostatics
AU1741601A (en) Mesenchymal stem cells and/or progenitor cells, their isolation and use
EP0681339A3 (en) Electrochemical cell.
GB2355579A8 (en) Molded electrode, method for production thereof, and secondary battery using the electrode
MXPA01011816A (en) Battery grid and method of making.
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
WO2000066732A3 (en) Laminin 8 and methods for its use
ZA9810371B (en) Th2 cell depletion; compositions; methods.
AU4391900A (en) Electrochemical cell
AU673414B2 (en) Cathodic active material composition for dry cells, method for preparing the same, and alkaline battery
PL354994A1 (en) Bio-supportive matrices, methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 615755

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000928524

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000928524

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000928524

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载